Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Padeliporfin potassium by ImPact Biotech for Non-Small Cell Lung Cancer: Likelihood of Approval
Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Non-Small Cell Lung Cancer. According...
Padeliporfin potassium by ImPact Biotech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to...
Padeliporfin potassium by ImPact Biotech for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase III for Transitional Cell Cancer (Urothelial Cell...
Padeliporfin potassium by ImPact Biotech for Esophageal Cancer: Likelihood of Approval
Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Esophageal Cancer. According to GlobalData,...